This is perhaps the biggest oversight of the whole program that requires immediate attention. Background: For years, pharmacists in many states have had the ability to prescribe, either by leveraging collaborative agreements with other providers (MDs, DOs, ARNPs, etc.) or autonomously through statewide protocols. There are varying degrees of permissions pharmacists have that are state-specific, but recognizing that prescriptive authority is within a pharmacist’s scope of practice is by all means nothing new. When the FDA released the EUA (emergency use authorization) fact sheets for these two antivirals, many in my profession were shocked that pharmacists were not included as eligible prescribers. It just doesn’t make any sense, and it is in direct opposition with the PREP Act that grants pharmacists broad prescriptive authority for COVID diagnostics, vaccines, and monoclonal antibodies. And what adds insult to injury is for states where pharmacists otherwise enjoy broad prescriptive authority like the state I practice in (Washington), there is no allowance for even creating a workaround by leveraging collaborative agreements like we would for most other drugs. A case could be made for pharmacies writing and operating under a collaborative agreement with a local provider anyway and then asking for forgiveness later, especially in rural and geographically-isolated areas with limited access and options for healthcare. It appears part of what drove the FDA’s decision to exclude pharmacists from having prescriptive authority had to do with the novel antivirals’ side effect profiles, drug interactions, contraindications, and dosing adjustment requirements with certain pre-existing conditions – the very areas in which pharmacists have exceptional clinical training and subject matter expertise. It may be time to re-educate regulators on who we are as pharmacists and what value we bring to care teams since we have long been recognized as The Medication Experts. Fortunately, we have many local, state, and federal advocates as well as virtually all pharmacy professional associations working hard to convince the FDA to reconsider its position.